Effects of spironolactone and eplerenone on left ventricular diastolic function and neurohumoral factors in patients with heart failure
Open Access
- 31 December 2020
- journal article
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 19 (6), 2464
- https://doi.org/10.15829/1728-8800-2020-2464
Abstract
Aim. To study the effects of spironolactone and eplerenone on left ventricular diastolic function and neurohumoral factors in patients with heart failure (HF).Material and methods. We examined 131 patients with coronary artery disease and NYHA class I-III HF. Patients were randomized into groups depending on HF class: class I (n=31), class II (n=51) and class III (n=49).Results. The study revealed that the clinical course of HF and LV diastolic dysfunction are associated with an increased level of neurohormones and are characterized by significantly high levels of aldosterone and norepinephrine in patients with a restrictiveLV diastolic dysfunction. A correlation was found between the level of neurohormones (aldosterone and norepinephrine) and heart remodeling parameters: an inverse correlation with an ejection fraction (r=-0,68, r=-0,61, respectively) and a direct correlation with LV end-diastolic volume (r=0,58, r=0,66, respectively). Long-term treatment with spironolactone and eplerenone had a positive effect, reducing the level of mentioned neurohormones. In patients with class II HF, both drugs had a positive effect on the level of aldosterone and norepinephrine, reducing them by 26,6% and 20,2% in the spironolactone group and by 28,4% and 24,6% in the eplerenone group, respectively. In patients with class III HF, the decrease in aldosterone level was more pronounced in those taking eplerenone than spironolactone: 32,1% vs 20,2%, respectively.Conclusion. In patients with HF, combination therapy with the inclusion of spironolactone significantly reduced the level of neurohormones mainly in patients with class II HF and, to a lesser extent, in those with class III HF. This suggests that combination therapy with spironolactone is less effective than with eplerenone in relation to neurohormones’ levels.Keywords
This publication has 14 references indexed in Scilit:
- Redefining the role of biomarkers in heart failure trials: expert consensus documentHeart Failure Reviews, 2017
- 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failureEuropean Heart Journal, 2016
- Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular ImagingJournal of the American Society of Echocardiography, 2016
- Afterload-induced diastolic dysfunction contributes to high filling pressures in experimental heart failure with preserved ejection fractionAmerican Journal of Physiology-Heart and Circulatory Physiology, 2015
- Prognostic Importance of Impaired Systolic Function in Heart Failure With Preserved Ejection Fraction and the Impact of SpironolactoneJournal of the American College of Cardiology, 2015
- The Framingham Heart Study and the epidemiology of cardiovascular disease: a historical perspectiveThe Lancet, 2013
- Pathological Ventricular RemodelingJournal of the American College of Cardiology, 2013
- Additional use of an aldosterone antagonist in patients with mild to moderate chronic heart failure: a systematic review and meta-analysisBritish Journal of Clinical Pharmacology, 2013
- Eplerenone and Atrial Fibrillation in Mild Systolic Heart Failure: Results From the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) StudyJournal of Invasive Cardiology, 2012
- Eplerenone in Patients with Systolic Heart Failure and Mild SymptomsThe New England Journal of Medicine, 2011